Guselkumab binding to CD64+ IL-23–producing myeloid cells enhances potency for neutralizing IL-23 signaling
Authors:
Open Access
- 12 March 2025
- journal article
- immunology
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1532852
Abstract
IL-23 is implicated in the pathogenesis of immune-mediated inflammatory diseases, and myeloid cells that express Fc gamma receptor 1 (FcγRI or CD64) on their surface have been recently identified as a primary source of IL-23 in inflamed tissue. Our complementary analyses of transcriptomic datasets from psoriasis and IBD showed increased expression of CD64 and IL-23 transcripts in inflamed tissue, and greater abundance of cell types with co-expression of CD64 and IL-23. These findings led us to explore potential implications of CD64 binding on the function of IL-23–targeting monoclonal antibodies (mAbs). Guselkumab and risankizumab are mAbs that target the IL-23p19 subunit. Guselkumab has a native Fc domain while risankizumab contains mutations that diminish binding to FcγRs. In flow cytometry assays, guselkumab, but not risankizumab, showed Fc-mediated binding to CD64 on IFNγ-primed monocytes. Guselkumab bound CD64 on IL-23–producing inflammatory monocytes and simultaneously captured IL-23 secreted from these cells. Guselkumab binding to CD64 did not induce cytokine production. In live-cell confocal imaging of CD64+ macrophages, guselkumab, but not risankizumab, mediated IL-23 internalization to low-pH intracellular compartments. Guselkumab and risankizumab demonstrated similar potency for inhibition of IL-23 signaling in cellular assays with exogenous addition of IL-23. However, in a co-culture of IL-23–producing CD64+ THP-1 cells with an IL-23–responsive reporter cell line, guselkumab demonstrated Fc-dependent enhanced potency compared to risankizumab for inhibiting IL-23 signaling. These in vitro data highlight the potential for guselkumab binding to CD64 in inflamed tissue to contribute to the potent neutralization of IL-23 at its cellular source.Keywords
This publication has 65 references indexed in Scilit:
- Targeting IL-23 for IBD: Rationale and Progress to DateDrugs, 2023
- Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo‐Controlled DISCOVER‐1 StudyACR Open Rheumatology, 2023
- Long‐Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through Two Years: Results From a Phase III, Randomized, Double‐Blind, Placebo‐Controlled Study Conducted in Biologic‐Naive Patients With Active Psoriatic ArthritisArthritis & Rheumatology, 2022
- The Conversion of Human Tissue‐Like Inflammatory Monocytes Into MacrophagesCurrent Protocols, 2021
- Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated ComorbiditiesDermatology and Therapy, 2021
- A two‐step human culture system replicates intestinal monocyte maturation cascade: Conversion of tissue‐like inflammatory monocytes into macrophagesEuropean Journal of Immunology, 2020
- Single-Cell Analysis of Crohn’s Disease Lesions Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-TNF TherapyCell, 2019
- Burkholderia pseudomallei induces IL-23 production in primary human monocytesMedical Microbiology and Immunology, 2015
- Kinetic analysis of a high-affinity antibody/antigen interaction performed by multiple Biacore usersAnalytical Biochemistry, 2006
- Two distinct regions of FC gamma RI initiate separate signalling pathways involved in endocytosis and phagocytosis.The EMBO Journal, 1995